Andrew Hollman Meyer - 27 Sep 2024 Form 4 Insider Report for Janux Therapeutics, Inc. (JANX)

Signature
/s/ James Pennington, Attorney-in-Fact
Issuer symbol
JANX
Transactions as of
27 Sep 2024
Net transactions value
-$2,087,255
Form type
4
Filing time
27 Sep 2024, 19:32:58 UTC
Previous filing
03 Jan 2024
Next filing
20 Dec 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JANX Common Stock Options Exercise $210,500 +50,000 +74% $4.21 117,592 27 Sep 2024 Direct F1
transaction JANX Common Stock Sale $2,297,755 -50,000 -43% $45.96 67,592 27 Sep 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JANX Stock Option (right to buy) Options Exercise $0 -50,000 -33% $0.000000 100,667 27 Sep 2024 Common Stock 50,000 $4.21 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 1,189 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan (the "Plan") on November 15, 2021, 1,752 shares acquired under the Plan on May 13, 2022, 2,401 shares acquired under the Plan on May 15, 2023 and 2,834 shares acquired under the Plan on May 15, 2024.
F2 The weighted average sale price for the transaction reported was $45.9551 and the range of prices were between $45.55 and $46.50. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F3 Immediately exercisable.